No Data
Sensei Biotherapeutics Says First Patient Dosed In Study FTH-PIK-101, Phase 1b/2 Trial Of PIKTOR In Patients With HR+/HER2- Advanced Breast Cancer
Express News | Sensei Biotherapeutics Doses First Patient in Phase 1B/2 Trial of Piktor in Hr+/Her2- Advanced Breast Cancer
Most and Least Shorted Healthcare Stocks With up to $2B Market Cap in May
Express News | Form 144 | Sensei Biotherapeutics(SNSE.US) 10% Stockholder Proposes to Sell 4.96 Million in Common Stocks
Sensei Biotherapeutics Files to Sell 24.87M Shares of Common Stock for Holders
Express News | Sensei Biotherapeutics Inc : Leerink Partners Initiates Coverage With Outperform Rating; Target Price $50